“Hot Comb Alopecia” Is a Name That Outlived Its Evidence

Central centrifugal cicatricial alopecia is a scarring hair loss. It starts at the crown and moves outward, it destroys follicles rather than thinning them, and the hair that is lost does not come back. It is the most common form of scarring alopecia in Black women.

For decades it was called hot comb alopecia, because when it was first described in 1968 the researchers noticed that the women who had it used hot combs, and drew the obvious conclusion.

The causal link never held up.

Subsequent work failed to establish that thermal straightening causes the condition. The name was formally changed. And yet the original framing has proved remarkably durable, because it is intuitive, because it is repeated in older textbooks that are still on shelves, and because it fits a story people were already inclined to believe — that this was self-inflicted, a consequence of women doing something avoidable to their hair.

Relaxers got folded into the same story. One study reported an odds ratio of 12.37 linking chemical relaxer use to the condition. It failed to replicate.

So the two things that women with CCCA were told they had done to themselves are: a heat tool that was never shown to cause it, and a chemical whose one striking association did not survive the next attempt to find it.

Where the evidence points now

Genetics, at least in part. A mutation in PADI3 — a gene involved in shaping the hair shaft — was found in 24 percent of a cohort of 58 patients, at p=0.04.

That is a small cohort and a modest p-value and I am not going to oversell it. Twenty-four percent is also not most patients, which means PADI3 is part of the picture rather than the picture. But it points somewhere entirely different from the styling story, and it is the most substantive finding the field has produced on causation in fifty years.

There is also an inflammatory component, and an emerging association with metabolic and fibrotic conditions that is being actively worked on. None of that is settled either. What is reasonably settled is that the confident causal account everyone was given was not supported.

Why the name mattered

Because a diagnosis that contains a cause changes the appointment.

A woman presenting with crown thinning, told she has hot comb alopecia, has been handed an explanation and an instruction in the same breath. Stop doing the thing. She stops doing the thing. It progresses anyway, because the thing was not the cause, and now the failure looks like non-compliance rather than a wrong hypothesis.

And the framing shapes what gets prescribed. If the cause is the patient’s styling, the treatment is behavior change, and the appointment is short. If the cause is inflammatory and partly genetic, the treatment is anti-inflammatory, early, aggressive, and the appointment is a referral. CCCA is a scarring alopecia — the window in which you can preserve follicles is the window before they scar, and a decade spent switching heat tools is a decade out of that window.

I do not think this was malice. It was a plausible hypothesis, published in 1968, that hardened into a name and then into a fact, and that nobody with enough standing revisited for a long time because the population it affected was not the population the field was organized around.

Catching it while the follicles are still there

Early is everything, and early looks like almost nothing: a slightly wider parting at the crown, a patch that feels smoother than the scalp around it, occasional tenderness or itching or a burning sensation in that area. The smoothness is the important one — scarring alopecia loses the follicular openings, so the skin goes shiny, and that is visible before the thinning is obvious.

A biopsy is reasonable and it is the thing that distinguishes this from the non-scarring hair loss it can look like. It is a small punch, it is not a big deal, and it changes the treatment entirely.

And if a clinician tells you to stop using heat and sends you away — that is 1968 advice. It is not necessarily wrong to reduce heat and tension, and it is not treatment for a scarring inflammatory condition.

Ask what the anti-inflammatory plan is. Ask whether a biopsy is warranted. Ask whether they have seen this before. Those three questions sort the room quickly.

This article is educational and is not a substitute for care from someone who can look at your skin. Anything new, changing, painful or spreading should be assessed rather than researched.